TerSera Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

TerSera Therapeutics is a private, commercial-stage biopharmaceutical company founded in 2015 and headquartered in Deerfield, Illinois. The company leverages a specialized business model centered on acquiring or in-licensing clinical-stage or approved small molecule therapeutics with untapped potential, then applying its expertise in development, commercialization, and patient support to maximize their impact. With a seasoned leadership team and a focus on addressing unmet medical needs, TerSera aims to deliver meaningful patient outcomes through its portfolio of 'one-and-only' therapies.

Small Molecules

Technology Platform

Integrated development, commercialization, and patient support expertise for advancing clinical-stage or approved small molecule therapeutics.

Funding History

1

UndisclosedUndisclosedUndisclosedJun 15, 2012

FDA Approved Drugs

1

XERMELONDAFeb 28, 2017

Opportunities

TerSera has the opportunity to establish a strong market position in niche therapeutic areas with high unmet needs, leveraging its integrated model to maximize the value of underappreciated assets.

By focusing on comprehensive patient support and real-world evidence generation, it can build durable relationships with providers and payers, creating barriers to entry for competitors.

Risk Factors

The company faces concentration risk if dependent on a limited product portfolio, and its acquisition-based model carries integration and valuation challenges.

Market access and reimbursement hurdles in specialty pharma, along with potential competition for attractive in-licensing targets, pose significant threats to growth and profitability.

Competitive Landscape

TerSera competes with other specialty pharmaceutical companies and biotechs that also focus on in-licensing and commercializing niche therapies. Its differentiation lies in its integrated patient-first approach and proven operational expertise. Larger pharma companies may be competitors in specific therapeutic areas but generally pursue larger market opportunities.

More companies in Small Molecule Drugs →More companies in United States →